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Cytotoxic T lymphocytes (CTLs) are key players in fighting cancer, and their induction is
a major focus in the design of therapeutic vaccines. Yet, therapeutic vaccine efficacy
is limited, in part due to the suboptimal vaccine processing by antigen-presenting
cells (APCs). Such processing typically takes place via the MHC class II pathway
for CD4 T-cell activation and MHC class I pathway for activation of CD8 CTLs. We
show that a combination of skin photochemical treatment and immunization, so-called
photochemical internalization (PCI) facilitated CTL activation due to the photochemical
adjuvant effect induced by photosensitizer, oxygen, and light. Mice were immunized
intradermally with antigen and photosensitizer, followed by controlled light exposure.
PCI-treated mice showed strong activation of CD8T cells, with improved IFN-γ
production and cytotoxicity, as compared to mice immunized without parallel PCI
treatment. Surprisingly, the CD8 T-cell effector functions were not impaired in MHC
class II- or CD4 T-cell-deficient mice. Moreover, PCI-based vaccination caused tumor
regression independent of MHC class II or CD4T cells presence in melanoma bearing
mice. Together, the data demonstrate that PCI can act as a powerful adjuvant in cancer
vaccines, even in hosts with impaired T-helper functions.
Keywords: vaccine, photochemical internalization, cancer immunotherapy, melanoma, cytotoxic T cells, T-helper
cells
INTRODUCTION
Therapeutic cancer vaccines, consisting of well-defined antigens, and carriers or adjuvants,
aim at inducing cytotoxic T cells (CTLs) specific for the tumor (1). The CTL activation
is primarily mediated by special subsets of dendritic cells (DCs), such as lymphoid
CD8α DCs, skin CD103 DCs, or CD207 Langerhans cells (2, 3),which process and
present antigens on MHC class I molecules. However, the processing of exogenous
antigens by DCs or other antigen-presenting cells (APCs) typically leads to MHC class
II antigen presentation to CD4T cells and it is generally recognized that CD4 T-helper
cells are required for optimal activation, expansion, homing, and maintenance of CTLs.
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A major challenge in the development of vaccines or antigen-
delivery systems is to design preparations that are capable of
delivering antigen to MHC class I molecules and, at the same
time, ensuring sufficient help from CD4T cells (1, 4). To this
end, strategies that enable direct cytosolic delivery of the antigen
either by translocation through the APC plasma membrane or
by antigen uptake and subsequent endosomal escape have shown
promising results (5–9).
Photochemical internalization (PCI) is a novel medical
approach that enables cytosolic targeting of drugs in combination
with a photosensitizer. Photosensitizer and drug are taken up by
endocytosis and upon light activation, reactive oxygen species
cause endosomal leakage, and translocation of the drug into the
cytosol (10). When using the PCI technology with antigens, we
have shown that in APCs PCI can mediate antigen delivery to
cytosolicMHC class I for activation of CD8T cells, at least in vitro
and in transgenic mouse models (11–15). The goal of the current
investigation was to study PCI-based immunization in wild type
mice and inmouse tumormodels. Moreover, since the hypothetic
mode of action of PCI is based on the endosomal disruption and
redirection of antigen presentation away from MHC class II, we
also investigated if the removal of CD4 T-cell help would affect




Female C57BL/6 (H-2Kb) mice were purchased from Envigo
(Horst, The Netherlands). Congenic CD45.1 (Ly5.1), MHC class
II- and CD40L-deficient mice were provided through SwIMMR,
the Swiss Immunological Mutant Mouse Repository (Schlieren,
Switzerland), and bred at the animal facility at the Biologische
Zentrallabor, University Hospital Zurich. All mice were kept
under SPF conditions, and the experimental procedures were
approved by the animal research ethics review board and
the Swiss veterinary authorities (licenses ZH 200/2014 and
ZH 52/2016).
Cells
Mouse melanoma B16-F10 cells (ATCC CRL-6475) transfected
for expression of OVA was kindly provided by Emmanuel
Contassot (University of Zürich). The cells were cultured in
RPMI-1640 medium (Sigma-Aldrich) supplemented with 8%
FCS, 50 mg/ml Normocin (InvivoGen), 2mM L-glutamine
(Life Technologies, Zug, Switzerland), and 1 mg/mL G-418
(Life Technologies).
Immunization and Photosensitization of
Mice
Mice were immunized with chicken egg albumin (OVA) from
Sigma-Aldrich (Buchs, Switzerland) and the photosensitizer
tetraphenyl chlorine disulfonate (TPCS2a) was provided by PCI
Biotech (Oslo, Norway). The mice received two intradermal
immunizations of each 50 µl in the abdominal region, of the
freshly prepared vaccines containing 100 µg of OVA and 50 µg
of TPCS2a (in a total volume of 100 µl). Eighteen hours after
the immunization, the mice were anesthetized with ketamine
(75 mg/kg) and xylazine (12 mg/kg) by intraperitoneal injection
and light-treated at 435 nm with LumiSource (PCI Biotech) for
6min (4.86 J/cm2) as previously described (12). Two booster
immunizations with 2 week intervals were typically given using
the same dosing and illumination regimens as for priming. Blood
and spleen were collected at different time points for further
analysis of T- and B-cell responses.
As an alternative source of antigen, mice were immunized
with lethally irradiated (50Gy) OVA-expressing B16 melanoma
cells (B16-OVA). After irradiation, the cells were washed,
suspended in PBS, and 1 × 106 cells were mixed with 50 µg of
TPCS2a and 1 µg of poly(I:C) (InvivoGen; Toulouse, France)
in 100 µl PBS and intradermally administered as described
for the immunization with OVA. Light treatment and boosting
immunizations were made as described for OVA.
CD4 T-Cell Depletion and MHC Class-II
Blocking
Depletion of CD4T cells was done by intraperitoneal
administration of a mixture of two monoclonal antibodies
isolated from the YTS 191.1.2 (1mg) and YTA 3.1.2 (1mg)
hybridoma cells (16). The antibodies were injected 1 day prior
to and 4 days after each immunization. Alternatively, and to test
whether CD4T cells were important during antigen presentation
or for some subsequent bystander effect, the antibodies were
injected 4 days after immunization only. The depletion efficacy
was verified by flow cytometry of the blood at different time
points after injection.
For the inhibition of MHC class II reactivity in vivo, 500 µg
of anti-MHC class II monoclonal antibody (clone M5/114 from
BioXcell; LubioScience, Zurich, Switzerland) was administered
intravenously 1 day before and 1 day after immunization (17).
Analysis of Antigen-Specific CD8 T-Cell
Responses by Flow Cytometry
Venous blood was collected and the erythrocytes were lysed
(with Red Blood Cell Lysing buffer, Hybrid-Max, Sigma)
before cell-surface staining was performed. Briefly, the cells
were stained for 30min with PE-labeled pentamer-OVA257−264
(5mer-SIINFEKL) from ProImmune (Oxford, United Kingdom)
and fluorescently labeled antibodies specific for mouse CD3,
CD4, CD8, CD44, and KLRG1 from eBiosciences (San Diego,
CA, USA). Dead cells were excluded by staining with 7-
Aminoactinomycin D (eBiosciences). All staining was performed
on ice and protected from light.
Intracellular protein staining on erythrocyte-free blood cells
or splenocytes was performed after overnight incubation of
cells with 2µM OVA aa257-264 peptide SIINFEKL (EMC
microcollections; Tuebingen, Germany) in the presence of
7.5µg/mL brefeldin A (Sigma-Aldrich). Briefly, the cells were
first surface-stained with fluorescently labeled antibodies against
mouse CD3, CD4, and CD8, and then fixed and permeabilized
using Cytofix/Cytoperm and Perm/Wash solutions from BD
Biosciences (San Diego, CA). Subsequently, the cells were stained
with fluorescently labeled antibodies against IFN-γ, TNF-α,
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perforin, granzyme B, or FasL (eBiosciences) for 60min. All
stainings were performed on ice and protected from light. Finally,
data was acquired on a BD Fortessa flow cytometer and analyzed
with FlowJo software v.10 (Tree Star, Ashland, Oregon, USA).
In vivo Cytotoxicity Assay
Splenocytes from naive CD45.1 mice were labeled with carboxy-
fluorescein succinimidyl ester (CFSE) (Molecular Probes; Leiden,
the Netherlands) at 5µM (target population) or 0.5µM (control
population) according to the provider. The CFSEhi target cells
were pulsed with 0.5µg/ml SIINFEKL peptide. After washing in
PBS, the antigen-pulsed CFSEhi target cells and the non-pulsed
CFSElo control cells were mixed in a 1:1 number ratio and 100
µl administered intravenously into the previously immunized
recipient C57BL/6 mice. Two days later, blood from these mice
was collected, and the frequency of target cells was analyzed by
flow cytometry. The percentage of specific killing was calculated















 x 100 % (1)
Tumor Growth Experiment in Mice
To test the effect of PCI-based immunization on the growth of
a mouse tumor, 2 × 105 OVA-expressing B16 melanoma cells
(B16-OVA) were injected subcutaneously into the flank of the
mice. Tumor vaccination was first tested in a prophylactic setting
where mice were immunized three times with 2 week intervals as
described above (days 0, 14, 28) and then challenged with 2× 105
B16-OVA tumor cells by subcutaneous injection 1 week after the
last vaccination (day 35). For therapeutic immunization, themice
were inoculated with 2 × 105 B16-OVA tumor cells, immunized
7 days later with OVA and TPCS2a, and illuminated next day as
described above. The immunizations were repeated weekly.
Antibody Measurements
OVA-specific serum antibodies were analyzed in blood collected
at different time points post immunization. Briefly, Maxisorb
ELISA plates were coated with 4µg/ml OVA and blocked
with skimmed milk. Serial dilutions of mouse sera were
applied and subsequently detected using biotinylated rat anti-
mouse-IgG1 and IgG2c antibodies (BD Pharmingen). After
ELISA development with strepatavidin-conjugated HRP (BD
Pharmingen) and TMB substrate (eBioscience), absorbance was
read at 450 nm using an ELISA plate reader from BioTek
instruments (Sursee, Switzerland).
Splenocyte Re-stimulation and Cytokine
Secretion Assays
After PCI-based immunization with OVA, spleens were
harvested, and the processed erythrocyte-free splenocytes were
plated at 5 × 105 cells per well in supplemented RPMI-1640
medium [with 8% FCS, 50 mg/ml Normocin (InvivoGen), 2mM
L-glutamine (Life Technologies, Zug, Switzerland), and 1 mg/mL
G-418 (Life Technologies)] and incubated with 10µg/ml OVA
at 37 ◦C for 20 or 96 h. Cytokine secretion into the supernatant
was measured using Ready-Set-GO! ELISA according to the
manufacturer (Invitrogen by Thermo Fischer, Zug, Switzerland).
Statistical Analysis
The statistical evaluations were performed using GraphPad
Prism 7 (GraphPad Software). The data distribution was
determined using a D’Agostino-Pearson normality test. If
normally distributed, the data was further analyzed by student
t-test or by two-way ANOVA. For non-parametric analysis, a
two-sided Mann Whitney test or a Kruskal-Wallis test with
Dunn’s correction was applied. The significance of differences
between the tumor survival curves was calculated with the log-
rank (plotted curves with Kaplan-Meier) test using R (version
3.3.3; R Core Team, 2017). The significance level was set to 95%.
RESULTS
PCI Facilitates Priming of Endogenous
Antigen-Specific CD8T Cells That Are
Maintained Independent of MHC Class II
Signaling
Wild type (WT) mice were immunized thrice with OVA or
OVA combined with PCI (Figure 1A), and antigen-specific CD8
T-cell proliferation and cytokine secretion were analyzed by
flow cytometry (Supplemental Figure 1). One week after the last
immunization (day 35), the frequency of antigen-specific CD8T
cells in blood had risen from 0.02% in non-immunized mice
to 0.15% in OVA-immunized mice (Figure 1B). In mice that
also received PCI treatment, a further 10-fold increase (1.25%)
was detected. Hence, PCI-supported immunization can facilitate
activation and proliferation of CD8T cells, in WT mice.
The hypothesized mechanism of PCI-based immunization
is the endosomal escape, cytosolic release, and MHC class I
presentation of processed antigen to CD8T cell. These events are
supposed to be triggered by light activation of photosensitizer
contained in DC endosomes and cause a diversion of the
antigen away from MHC class II presentation. Hence, we
investigated if host MHC class II molecules were required in
intradermal OVA immunization as a function of PCI support.
MHC class II-deficient (MHCII ko) mice were immunized with
OVA with or without PCI. The MHCII ko mice were expectedly
lacking CD4T cells (Figure 1C). Immunization with OVA alone
resulted in weak antigen-specific CD8 T-cell proliferation in
WT mice (Figure 1D), and no measurable response in MHCII
ko mice (Figure 1E). Surprisingly, activation and proliferation
CD8 T-cells were not impaired in MHCII ko mice when OVA
immunization was combined with PCI (Figure 1E). Indeed, the
measured frequencies of antigen-specific CD8T cells in blood
from MHCII ko were 15% (Figure 1E) while typically 1–5%
in WT mice (Figure 1D and data not shown from replica
experiments). In addition, the capability of the CD8T cells to
produce interferon-γ (IFN-γ) was maintained independently
of MHCII for PCI-based immunization (Figures 1D,E). Since
MHCII ko mice were deficient both in MHCII and in CD4T
cells, and to test if the PCI-associated amplification of CD8 T-
cell responses in MHCII ko mice was associated with the lack
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FIGURE 1 | PCI facilitates CD8 T-cell proliferation and cytokine secretion independent of MHC class II and CD40L. (A) Schematic depiction of the experiment: Wild
type C57BL/6 mice (WT) or syngeneic MHCII ko or CD40L ko mice were immunized with OVA or OVA combined with PCI and treated as illustrated in the scheme.
(B) Antigen-specific CD8 T-cell responses in blood on day 35 following immunization in WT mice. (C) Expression of CD4, CD8, and SIINFEKL- specific (CD8) cells in
WT and MHCII ko mice by flow cytometry. (D,E,G) Frequencies of SIINFEKL-specific CD8T cells in blood on day 35 in WT, MHCII ko, and CD40L ko mice, and
intracellular IFN-γ analysis after ex vivo re-stimulation of blood cells from immunized WT (D), MHCII ko (E), and CD40L ko (G) mice. (F) WT mice were treated with
MHCII-blocking antibodies and immunized as above with OVA and PCI. SIINFEKL-specific IFN-γ production was measured in spleen cells after ex vivo re-stimulation.
(H) Groups of 5 WT and MHCII ko mice were immunized thrice with OVA and PCI and challenged with 2 × 105 B16-OVA melanoma cells subcutaneously. Tumor
growth in individual mice (H) and Kaplan Meier survival plots (I) are shown. *p ≤ 0.05, **p < 0.01 calculated by non-parametric Mann-Whitney test. The experiments
in WT and MHCII ko mice were performed at least three times with comparable results. The experiment in CD40L mice was performed twice. Shown are means +
SEM from one representative (n = 5 mice per group). The tumor challenge experiment was performed twice with comparable results. P = 0.007 comparing
non-immunized WT mice (Untr) to immunized WT or MHCII ko mice and evaluated with the log-rank test of the Kaplan-Meier curves.
of MHCII or the lack of CD4T cells, WT mice were treated
with anti-MHC class II antibody and immunized. The blocking
of MHC class II did not affect CD8 T-cell activation and IFN-
γ production (Figure 1F). Hence, PCI- based immunization
enabled the priming and maintenance of endogenous antigen-
specific CD8T cells, independently of MHC class II signaling. Of
note, the PCI-facilitated activation of CD8T cells was dependent
on light-activation of the photosensitizer, since immunization
with antigen and TPCS2a without application of light did not
trigger antigen-specific CD8 T-cell proliferation and cytokine
secretion for OVA (Supplemental Figure 2) or for other antigens
(unpublished data).
PCI Facilitates CD8T Cell-Priming
Independent of CD40-CD40L Signaling
CD40L on CD4T cells may interact with CD40 on APCs and
thereby provide co-stimulatory signals that help effective priming
of CD8T cells. Since PCI enabled CD8 T-cell activation in
the absence of CD4T cells, we tested whether CD40 signaling
was dispensable in PCI-based immunization. To this end,
CD40L-deficient mice were immunized. Neither proliferation
nor IFN-γ production (Figure 1G) of SIINFEKL-specific CD8T
cells depended on CD40-signaling when immunization was
combined with PCI. In immunized mice that were not PCI
treated, the responses in WT and CD40L ko mice were
comparably low. These results suggest that the PCI-facilitated
priming of antigen-specific CD8T cells takes place independent
of CD40.
PCI-Based Vaccination Prevents
Subsequent Growth of Mouse Melanoma
Independent of MHC Class II Signaling
PCI-based vaccination and the role of T helper cells and
MHCII signaling in PCI-based vaccination was further studied
in a mouse tumor model. WT and MHC class II-deficient
mice were treated fortnightly with OVA protein and by PCI
as described above (Figure 1A), and 1 week after the last
booster, the mice were challenged with B16-OVA cells. Tumor
growth (Figure 1H) and survival (Figure 1I) were significantly
delayed in vaccinated mice as compared to non-vaccinated
mice, independent of MHC class II. The mean survival times
for untreated, WT, and MHCII ko mice were 18, 33, and 30
days, respectively.
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CD8 T-Cell Activation Is Not Impaired, but
Long-Lasting After CD4 T-Cell Depletion
To further study how CD4T cells affected PCI-based
immunization during antigen presentation, we removed
CD4T cells in WT mice by intraperitoneal injections of CD4
T-cell depleting antibodies 1 day prior to and 4 days after each of
the three immunizations (Figure 2A). The CD4 T- cell depletion
was complete within 1 day of antibody injection, lasted for at
least 2 days after the last antibody injection (Figure 2B), and
produced a CD4 phenotype similar to that of MHCII ko mice,
which were used as CD4-deficient control (Figure 1C). By day
12, the CD4 T-cell population largely recovered in mice receiving
depleting antibodies.
Typically, antigen-specific CD8T cells were not observed after
the primary immunization, but were clearly detectable upon a
first booster injection, especially in MHCII ko mice, but also
in WT and CD4 T-cell depleted mice (Figure 2C). Maximum
frequencies of SIINFEKL-specific CD8T cells in blood were
determined 1 week after the second booster, and were 15, 12,
and 5% for MHCII ko, CD4 T-cell-depleted, and WT mice,
respectively. Thereafter, the frequencies decreased comparably,
independent of CD4T cells or MHC class II. Hence, neither
MHC class II signaling nor CD4 T-helper cells were required
for PCI-mediated stimulation of CD8 T-cell responses, and the
two tested models of CD4 T-cell deficiency were comparable.
On week 12, i.e., 8 weeks after the last booster, SIINFEKL-
specific CD8T cells were comparable through all groups with
frequencies close to baseline levels. Here, blood (Figure 2D)
and spleen (Figure 2E) cells were isolated and re-stimulated in
vitro with SIINFEKL. In general, lymphocytes from immunized
WT mice revealed significantly stronger recall effects than cells
from untreated mice as measured by the expression of KLRG1
and the secretion of IFN-γ and TNF-α cytokines. Hence, the
results suggest that PCI-based immunization triggered functional
CD8 T-cell memory. Moreover, the functional memory was
independent of CD4T cells or MHC class II, since KLRG1
expression and cytokine secretions were not reduced in MHCII
ko and CD4 T-cell depleted mice as compared with WT mice.
The depletion of CD4 T-cells by injection of depleting
antibodies 4 days after each immunization had no effect on the
CD8 T-cell activation when compared with the WT mice (data
not shown). In order to test if the WT CD4 T-cell population
contained an immune suppressive factor that negatively affected
the CTL activation, MHCII ko mice received an adoptive transfer
of purifiedWTCD4T cells or Foxp3- and CD25- CD4 regulatory
T cells (Tregs) prior to the PCI-based immunization. No CTL-
specific immunosuppressive effects of the transfer were observed
(Supplemental Figure 3). Therefore, with these experiments, we
confirmed activation and long-lasting functions of CD8T cells in
mice even in the absence of CD4 T-helper cells.
Cytotoxicity Upon PCI-Based
Immunization Is Not Dependent on MHC
Class II or CD4 T- Cell Help
Assessment of in vivo cytotoxicity showed that PCI-based
immunization also induced cytotoxic functions, and again, the
property was not dependent on CD4T cells or MHC class II
signaling (Figure 2F). In fact, the measured cytotoxicity was
nearly 100% in immunized MHC class II-deficient and in CD4
T-cell-depleted mice, while only 73% in immunized WT mice
(Figure 2G). In contrast, the expression of cytolytic mediators
such as perforin, granzyme B, and FasL was upregulated on
CD8T cells from WT mice, but not on CD8T cells from
MHC class II-deficient and from CD4 T-cell-depleted mice
(Figures 2H–J). Hence, PCI-based immunization mediates CD4
T-cell-independent cytotoxicity, but it seemed that the induced
expression of the cytolytic proteins perforin, granzyme B, and
FasL depended on co-stimulatory or bystander signals from
T-helper cells.
Therapeutic PCI-Based Vaccination
Suppressed Growth of Melanoma
Independent of CD4 T Cells
PCI-based CTL vaccination was also tested in a therapeutic
setting of tumor-bearing mice, including that of CD4 T-cell-
depleted mice. Seven days after the inoculation of the melanoma
cells, at which time point a solid tumor was visible palpable,
the mice were vaccinated and PCI treated with weekly intervals
(Figure 3A). For depletion of CD4T cells, anti-CD4-depleting
antibodies were administered 1 day prior to each vaccination
session. The tumor grew fast in non-vaccinated control mice,
while the growth was delayed in vaccinated mice (Figure 3B).
The lack of CD4T cells did not notably impair anti-tumor
immune responses in immunized mice, the melanoma growth
and mouse survival being comparable in WT and in CD4 T-
cell-depleted mice (Figure 3C). The mean survival time for
untreated, WT, and CD4-depleted mice were 19, 28, and 30 days,
respectively, pointing out the therapeutic effect of PCI-based
vaccination against melanoma, independent of CD4 T cells.
PCI-Based Vaccination With
Melanoma-Associated Antigens Is Also
Independent of T-Cell Help
To test the added immunological effect of PCI on cancer
vaccination on other antigens than OVA, we immunized mice
as for OVA but using irradiated B16-OVA melanoma cells as
antigen. The cells naturally express known melanoma antigens
such as gp100 and Trp2 but were engineered to also express
OVA. Again, the vaccination was followed 1 day later by PCI
treatment, and one group of mice was treated with CD4-
depleting antibodies prior to each vaccination session. After
re-stimulation of blood lymphocytes ex vivo with melanoma
Trp2 or OVA peptides, significant CD8 T-cell responses against
both antigens could be detected, and the responses were not
dependent on CD4 T-cell help (Figure 4A). One day after the
last of three vaccinations (day 29), all mice were challenged with
live melanoma cells and the tumor growth monitored. None of
the immunized mice showed tumor growth (Figure 4B), and
the mice were protected beyond day 22 post-tumor challenge
independently of the presence of CD4 T-helper cells (Figure 4C).
On day 22 after the tumor challenge, the mice were euthanized,
the purified CD8T cells from spleens and lymph nodes were
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FIGURE 2 | PCI-mediated immune responses are long lasting, independent of CD4 T-helper cells and cytotoxic. (A) Schematic depiction of the experiment: WT or
MHCII ko mice were immunized thrice with OVA and PCI. Additionally, WT mice were treated with CD4-depleting antibodies, whereas complete untreated mice were
also included. (B) The effects of anti- CD4 depletion monitored by flow cytometry prior to treatment on day 7 and 12. (C) Kinetics of SIINFELK-specific CD8T cells in
blood was monitored by flow cytometry. Blood cells (D) and spleen cells (E) were analyzed eight (D) and nine (E) weeks after the last immunization for frequencies of
SIINFEKL-specific and KLRG1-expressing CD8 and CD44-positive lymphocytes, intracellular IFN-γ-production, IFN-γ, and TNF-α double-producing CD8T cells.
(F–H) Mice were immunized as shown in the scheme (A), and cytotoxicity (F,G) was measured in vivo with SIINFEKL-loaded and CFSE loaded spleen cells from
CD45.1 mice. The mean percentages of the killing activity are presented based on the frequency of target cells detected in blood. (F) Representative flow-cytometry
histograms of SIINFEKL-loaded CFSEhigh target cells (right peak) and CFSElow control cells (left peak). (G) Summary plot. (H–J) Seven days after the target-cell
transfer, CD8T cells present in spleen of the immunized mice were analyzed for the expression of perforin (H), granzyme B (I), and FasL (J). The experiments were
performed at least twice with comparable results. *p ≤ 0.05 and **p < 0.01 analyzed with Kruskal-Wallis. Shown are means + SEM (n = 5 mice per group).
FIGURE 3 | PCI-mediated immunization prevents melanoma growth in mice independent on CD4 T-cell help. (A)WT mice were injected subcutaneously with 2 × 105
B16-OVA melanoma cells and were therapeutically immunized weekly with OVA and PCI as indicated in the scheme. One group of mice was additionally treated with
CD4 T-cell depleting antibodies on days 6, 13, and 20. (B) Tumor growth in individual mice (n = 4–8 mice per group). (C) Kaplan Meier survival plots. p < 0.001 and
evaluated with the log-rank of the Kaplan-Meier curve. The experiments were performed twice with comparable results.
Frontiers in Immunology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1548
Varypataki et al. Light-Mediated Vaccination T-Help Independent
adoptively transferred into naïve WT hosts, and the hosts were
then challenged with live melanoma cells to test the fitness
of non-helped CD8T cells (Figure 4D). Control mice were
adoptively transferred with purified CD8T cells from naïve mice.
Tumor growth was observed in all mice, but the growth was
delayed in mice that had received CD8T cells from immunized
mice as compared to the mice that had received naïve CD8T cells
(Figure 4E). Moreover, the melanoma growth was also delayed in
mice that had received non-helped CD8T cells from immunized
CD4-T-cell-depleted mice. The Kaplan Meier curves (Figure 4F)
revealed a median survival time of 20 days of the mice that had
received naïve CD8T cells (“Untr”) and a survival benefit for all
immunized mice (p = 0.012). For mice that received immune
CD8T cells, there was a survival benefit for non-helped CD8T
cells over mice that received helped CD8T cells (p = 0.012),
the median survival times being 35 and 27 days, respectively.
As for the model protein OVA, potential therapeutic effect of
PCI-based vaccination was also observed with tumor-relevant
antigens. Moreover, the results also suggest that the PCI method
of vaccination is also applicable to cellular vaccines and not only
to the so-far tested soluble protein vaccines.
Increased CD8 T-Cell Responses by PCI
Did Not Impair CD4 T-Cell Dependent
Antibody Responses
While PCI-based immunization clearly facilitated CD8 T-cell
responses independent of helper T cells, it is thus far unclear
whether PCI also aids the stimulation of CD4 T-cell responses
or T-cell mediated B-cell responses. To address this question,
WT, CD40L ko, and MHCII ko mice were immunized thrice
with OVA or with OVA combined with PCI, as described
above (cf. Figure 1A). Two weeks after the third immunization,
spleens were harvested and the cells re-stimulated in vitro with
OVA protein, MHCI-binding OT-I peptide (OVA aa257-264:
SIINFEKL), or MHCII-binding OT-II peptide (OVA aa323-338).
FIGURE 4 | Antigen-specific CD8 T-cell responses and tumor remission after immunization with irradiated melanoma cells and PCI treatment. Mice were immunized
on days 0, 14, and 28 with irradiated B16-OVA melanoma cells ± PCI. (A) On day 21, IFN-γ cytokine production was measured in blood cells after re-stimulation with
melanoma Trp2 (top) or SIINFEKL (bottom) peptides. Shown are means + SEM (n = 4–5 mice per group). On day 29, mice were challenged with 2 × 105 B16-OVA
cells subcutaneously and (B) tumor growth and (C) survival were monitored. The p value (p = 0.008) was calculated by log-rank analysis of the Kaplan-Meier curves
comparing non-immunized mice with any of the two immunized groups. (D) On day 22 after tumor inoculation, mice were euthanized, and CD8T cells were
MACS-sorted and adoptively transferred into groups of four naïve WT mice (1.5 × 107 cells/mouse). The recipient mice were then challenged with B16-OVA cells as
above. (E) Tumor growth and (F) survival were monitored. *p ≤ 0.05 and **p < 0.01 analyzed with Kruskal-Wallis. Pairwise comparison indicate that transfer of
immune CD8T cells caused significant survival benefit over the transfer of naïve CD8T cells (p < 0.012) when calculated by log-rank analysis of the Kaplan-Meier
curves. The experiments were performed twice with comparable results.
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Re-stimulation with OVA protein enabled us to study mixed
CD4 and CD8 T-cell responses, while OT-I and OT-II peptides
stimulate specific CD8 and CD4 T-cell subsets, respectively. The
cell culture supernatants were assessed for IFN-γ, TNF-α, or IL-
2 cytokines. OVA protein caused a strong secretion of IFN-γ
in cells from mice immunized with PCI support (Figure 5A).
As observed by flow cytometry above (cf. Figures 1D–F), the
IFN-γ secretion was particularly strong in MHCII- and CD40L-
deficient cells. The IFN-γ was primarily produced by OT-I-
reactive CD8T cells, as re-stimulation with OT-I and OVA
protein produced similar levels of IFN-γ. For cells stimulated
with OT-II peptide, little IFN-γ secretion was measured and
only in cells from CD40L ko mice that were immunized with
PCI support. Significant release of TNF-α was also observed in
CD40L- and MHCII-deficient cells after stimulation with OVA,
and the effect was facilitated by PCI treatment (Figure 5B).
OVA-specific IL-2 secretion was comparable in cells from
immunized WT or CD40L ko mice, independent of PCI
treatment (Figure 5C). As for IFN-γ secretion, the TNF-α and
especially the IL-2 secretion was SIINFEKL specific and highly
elevated in cells from PCI-treated MHCII ko mice. No OT-II-
specific TNF-α and IL-2 secretion were observed.
Since CD4 T-cell responses were almost undetectable, we
also analyzed mouse sera for OVA-specific antibodies, which are
expected to be CD4 T-cell dependent due to the requirement for
CD4 T-helper cells for B-cell activation. Prior to and 14 days
after each immunization, the mice were bled for analysis of OVA-
specific antibodies in serum. Both IgG1 (Figure 5D) and IgG2b
(Figure 5E) were induced in WT mice, independently of the
PCI treatment. In contrast, no IgG3 antibody responses were
observed (data not shown), an isotype that is often induced by
T-cell independent antigens (p < 0.01 by two-way ANOVA).
The igG1 and IgG2b antibody responses were slightly higher in
PCI-treated mice than in mice that received OVA immunization
only. A sero-conversion was observed on day 13, hence after a
single immunization, and the response plateaued after the second
immunization. No OVA-specific antibody response was observed
in CD40L ko and in MHCII ko mice.
DISCUSSION
Cancer vaccines can trigger endogenous immune responses to
autologous tumors, including such leading to tumor remission.
Typically, the protective cellular responses have been ascribed to
CD8T cells, since tumor cells express little, if any, MHC class II
molecules (18). Unfortunately, the therapeutic benefits of cancer
vaccines are still ambiguous, in part due to immunosuppressive
signals produced by the tumors, which also include the
down regulation of MHC class I molecules (19). Hence, it is
important to develop strategies that trigger strong tumor-specific
cytotoxic immune responses, while overcoming potentially
immunosuppressive tumor microenvironments.
While it is well recognized that CD8-positive CTLs are
important players in the immune surveillance of tumors, there
is an ongoing controversy concerning the importance of CD4
T-cell help for the induction of CTLs (20–24). Antigen-specific
CD4T cells can improve expansion of cognate and tumor-
specific memory CD8T cells (25), enhance recruitment and
infiltration of CD8T cells into tumors (26), help overcoming
immunosuppressive reactions in the tumor microenvironment
(27), and facilitate adoptive CD8T cell tumor therapy (28). In one
study, tumor-specific CD8T cells were activated independently
of CD4T cells, but required Th1-polarized CD4T cells for
effective tumor suppression (29). Similar CD4 T-helper support
functions have been reported in viral infections or anti-viral
vaccination (30). Nonetheless, other studies concluded that T-
helper cells are required merely for the priming of CTLs cells
(31), or for the maintenance of CD8 T-cell memory (22, 32).
Yet, functional CD8 T-cell responses were also shown to develop
without contribution of CD4T cells (33–35), the help in part
being replaced by signals provided through activation of pattern
recognition receptors such as Toll-like receptors (36). Since
cancer vaccination aims at triggering cytotoxic and tumor-
specific CTLs, it is important to understand how CD4 T-helper
cells may contribute to CTL priming, function and survival in
the context of cancer vaccines.
Most recently, vaccination and parallel photochemical
treatment, so-called PCI-based vaccination, was described as a
novel vaccination method that can trigger CTLs, at least in vitro
and in transgenic mice using OVA as model antigen (12, 13, 15).
The current study builds on these studies with two objectives.
Firstly, does PCI facilitate CD8 T-cell activation in vivo in wild
type mice? Secondly, how are the T-helper requirements in such
an experimental setting, bearing in mind that PCI is expected to
cause translocation of antigen away from the default MHC class
II pathway of antigen presentation?
The data generated in the current study fully supported
previous in vitro data and data using transgenic mice recognizing
OVA antigen. We primarily applied OVA in the current study,
but we could also demonstrate that PCI-based vaccination
using lethally irradiated melanoma cells caused activation of
melanoma specific CD8 T-cell responses. Hence, the data
represents a proof of principle and provide arguments to take
the technology a step further toward testing in other pre-
clinical models or even clinical trials. Indeed, a phase I trial
is currently performed to investigate the safety of intradermal
administration of photosensitizer and subsequent light treatment
(ClinicalTrials.gov Identifier: NCT02947854).
Regarding the second research objective, the hypothesized
mechanism of action of PCI-based vaccination included the
diversion of antigen from default MHC class II- toward a MHC
class I-pathway of antigen presentation. Indeed, PCI facilitated
a shift in the immune response from MHC class II-restricted
CD4 T-cell and B-cell responses toward CD8 T-cell responses
(12, 13). However, if priming of CTLs depends on CD4 T-
helper cells, the obvious question is how bypassing MHC class II
affects CTL activation. The current work suggests that PCI-based
vaccination elicits strong and functional CD8 T-cell responses,
independently of help from CD4T cells. The study also suggest
that PCI-based vaccinationmay be considered a treatment option
in cancer immunotherapy alongside other new vaccination
strategies and immunotherapies. While previous studies used T-
cell-receptor transgenic mouse models and the model antigen
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FIGURE 5 | CD8 T-cell-mediated cytokine secretion but not B-cell-mediated antibody production is independent of T helper cells upon PCI-based immunization. Wild
type C57BL/6 mice (WT) or syngeneic MHCII ko or CD40L ko mice were immunized on day 0, 14, and 31 with OVA (black symbols and white bars) or OVA combined
with PCI (red symbols and bars). The mice were bled for analysis of antibodies on days 0, 13, 30, and 55. (A–C) Spleen cells were harvested on day 55 and
re-stimulated in vitro with OVA protein (left panel), MHCI-binding OVA aa257-264 (middle panel), or MHCII-binding OVA aa323-338 (right panel). The supernatants
were harvested after 72 h (A: IFN-γ and B: TNF-α) or 24 h (C: IL-2) and the cytokine secretion analyzed by ELISA; *p ≤ 0.05 analyzed with Mann Whitney and
comparing PCI vs. non-PCI within each strain. The blood serum was analyzed on day 0, 13, 30, and 55 for OVA-specific (D) IgG1 and (E) IgG2b by ELISA. Results
are expressed as optical density at a serum dilution of 1:1,600 for IgG1 and 1:800 for IgG2b and analyzed by two-way ANOVA comparing PCI vs. non-PCI within
each strain.
OVA to proof the concept of PCI-based CTL vaccination (12,
13, 15), the current study showed vaccine efficacy in WT mice,
using different antigens (OVA and melanoma antigens), as well
as different antigen vehicles (soluble protein and irradiated
tumor cells).
The observed quality of the anti-tumor and CD8 T-cell
mediated immune responses in MHC class II-deficient mice was
both striking and surprising. The fact that naïve MHCII ko mice
have a slightly higher number of CD8T cells than the WT mice
can only partly explain the result. Moreover, the improved CTL
activation in MHCII ko mice did not appear to be a result of the
lack of MHC class II expression per se, as treatment of WT mice
with anti-MHC class II antibodies did not affect CTL activation.
It was rather the lack of CD4T cells in MHCII ko mice that
mediated the favorable CTL effect, because transient depletion
of CD4T cells using CD4 T-cell depleting antibodies strongly
facilitated CD8 T-cell responses as well as tumor remission. Of
note, the “beneficial” effect of lacking CD4T cells seemed to be
mediated by a mechanism active during antigen presentation
and not by a later and general bystander effect of CD4T cells.
When CD4T cells were depleted a few days after the vaccine
administration, no improved effect of CD8 T-cell activation
was observed.
Hence, how could the lack of CD4T cells be beneficial
for CTL activation, or how can CD4T cells prevent optimal
CTL activation? Numerous studies have demonstrated the
potential immune suppressive mechanisms of regulatory CD4T
cells (Tregs) (37). Through ligation with the co-stimulatory
molecules CD80 and CD86 molecules on the surface APCs, the
inhibitory receptor CTLA-4 is a potent mediator of Treg-induced
immunosuppression (38). The impact of preventing CTLA-4-
mediated suppression has become evident in melanoma patients
where the blocking of this checkpoint has improved treatment
success and life expectancy (39). The depletion of Tregs has
also been shown to delay tumor growth upon vaccination in
melanoma-bearing mice (40), while depletion of the whole CD4
T-cell population showed no such effect (35). Co-stimulatory
signals to CD8T cells can also be transferred via CD27-CD70
interactions (36, 41), and Tregs have been shown to inhibit anti-
tumor CTLs, in part by an enhanced CD70 sensitivity (42).
The CD27 receptor is expressed on CD4T cells, naïve CD8T
cells, natural-killer cells, and B cells, while the CD70 ligand is
upregulated on activated DCs and along with CD80 and CD86.
However, the expression of CD70 on DCs was not reduced in
CD4-depleted mice, and CD27 was essential for the generation
of helped CTLs and for their secondary expansion. Since the
exact mechanism by which PCI improves CTL vaccination is
not known, we speculated that the absence of Tregs in MHCII-
and CD4 T-cell-deficient mice could be contributing to the
improved CD8 T-cell responses that we observed upon PCI-
based vaccination, but not upon conventional vaccination. We
tested this by using an adoptive transfer of purified WT CD4T
cells or Tregs into MHCII ko mice prior to their immunization.
However, the CD8 T-cell responses remained high in the
adoptively transferred MHCII mice. Therefore, the facilitated
CD8 T-cell responses in MHCII- and CD4 T-cell-deficient mice
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upon PCI-based immunization is unlikely caused by the lack of
potentially immune-suppressing Tregs.
In order to gain insight into the role of CD4T cells on CTL
activation, we studied the pathways by which CTL responses
are triggered. One of the principal mechanisms by which CD4T
cells help the CTL cells priming is via licensing of DCs through
the CD40-CD40L interactions, leading to maturation of DCs
prior to their priming of CD8T cells (43). In the absence
of CD4T cells, CD40 signaling can substitute the otherwise
required T-helper signals, and the administration of agonistic
anti-CD40 antibodies can improve vaccine efficacy in CD4 T-cell
deficient conditions (34). Moreover, a subset of CD8T cells can
express CD40L allowing an autocrine activation of CD8T cells
independent of T-helper cells (43). In the current study, we
showed that PCI-based vaccination was CD4 T-cell independent,
but that the T-helper signals were not substituted by CD40
signals, since CD8 T-cell responses were not impaired in CD40L-
deficient mice.
The above-mentioned findings suggest that, not CD40 but
another signaling pathway, may provide the co-stimulation
and activation of CD8T cells when immunizing with PCI in
the absence of MHCII or CD4T cells. To this end, T-helper
signals have also been shown to be bypassed with innate danger
signals, e.g., TLR signals and pro-inflammatory cytokines that
can directly activate APCs for cross-priming of antigen to CD8T
cells (44). In the absence of T-helper cells, CTLs could be induced
when short MHC class I-binding peptides were co-administered
with TLR3 and TLR9 ligands, but not with TLR2, TLR4, TLR6,
or TLR7 ligands (45). In the current study, although we did
not use any adjuvant combined with the PCI treatment, we
cannot exclude the possibility that the photochemical reaction
induced by PCI induces danger signals that eventually act on
inflammatory pathways through up-regulation of cytokines and
other inflammatory proteins. Although, PCI-based vaccination
in MyD88- or TRIF-deficient mice did not suggest a PCI-
mediated TLR-effect (unpublished data), it will be important
to investigate the inflammatory reactions induced by PCI
and how these affect antigen presentation. A recent study
on using PCI for peptide vaccination shows that in vitro
PCI can increase CD86 expression in APCs, indicating that
the photochemical treatment may have an inherent adjuvant
activity (46).
Since PCI-based vaccination is applied intradermally, dermal
DCs at the injection site are likely the targeted cells. Although,
the exact subsets of DCs involved and the duration of
such activation remain unknown, pro-inflammatory cytokines
can directly activate APCs for cross-priming of antigen to
CD8T cells (44). Clinical data revealed that elevated IFN-γ
expression in the tumor is associated with improved survival
in melanoma (47). IFN-γ can also mediate upregulation of
MHC class I and class II molecules and of antigen processing
and presentation, which again may enhance recognition of
tumor-associated antigens by T cells (48). The migration of
T cells from lymph nodes to the tumor is also induced by
IFN-γ and the cytokine can induce expression of the IFN-
responsive chemokines (49). In the current study, PCI especially
facilitated strong IFN-γ production by CD8T cells and one
may speculate that this property may contribute to the T-helper
cell independency.
One possible pitfall of a vaccination method that facilitates
MHC class I-restricted antigen presentation concerns the
potential activation of autoimmune responses. Normally, the
presentation of self-antigens takes place in the absence of
inflammation, leading to anergy, or apoptosis of the T cells.
However, since PCI is followed by local inflammation, the
APCs may be equipped with co-stimulatory molecules, a process
that in the end may lead to a break of peripheral tolerance.
We have not observed signs of autoimmune responses with
PCI, but such processes are typically slow, for which reason
long-term studies would need to be performed. On the other
hand, since PCI-based vaccination would be applied to cancer
patients, a risks-benefit assessment would anyhow be required.
However, the currently and widely applied immunotherapies
with checkpoint inhibitors similarly increases the risk of
immune-related adverse events, including a potential shift
from self-tolerance to autoimmunity. Hence, this potential
adverse event is not only an attribute to PCI-based vaccination.
Nonetheless, this is a topic that must be kept in mind in future
studies of PCI-based vaccination.
In closing, the presented data clearly demonstrates that PCI-
based vaccination is an effective method for stimulation of
tumor-specific CTLs, and that these CD8T cells can suppress
tumor growth. Interestingly, the mechanism by which PCI-based
vaccination exerted its action was strictly independent of CD4
T-helper cells, at least in mice. Even in the absence of such
bystander help, the CTLs had effector and memory phenotypes
similar to wild type immune responses and prevented melanoma
growth in mice, both in prophylactic and therapeutic setting.
Although the exact mechanism by which PCI circumvents the
need of CD4 T-cell help in vaccination is not known, this feature
could be of therapeutic relevance. It shows that therapeutic
vaccination may be feasible in situations where patients manifest
with CD4 T-cell deficiency, for instance due to disease or medical
immune suppression. At present, this new method of CTL
vaccination is also validated in a first clinical human trial, the
primary objective being the incidences of adverse events after a
single administration of photosensitizer and light, but immune
response to co-administered human papilloma virus E7 (HPV
E7) and keyhole limpet hemocyanin (KLH) antigens will be
assessed in blood (NCT02947854).
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